Premium heart rate strap will now track pace and distance during indoor runs, giving athletes even more data to push their limits OLATHE, Kan.–(BUSINESS WIRE)–Garmin® International, Inc., a unit of Garmin Ltd. (NYSE: GRMN), today announced the HRM-Pro™ Plus, a premium heart rate strap that adds pace and distance data while continuing to provide athletes … [Read more…]
Webcast of Capital Markets Day on August 3 will include discussion of fiscal fourth-quarter results ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will release fourth-quarter results the evening of August 2. In lieu of hosting a quarterly earnings conference call, CSI management will discuss fourth-quarter results at the beginning of its capital markets … [Read more…]
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022. The … [Read more…]
LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and LimaCorporate S.p.A., a global orthopedic company focused on digital innovation and patient-tailored hardware, today announced a licensing partnership for the U.S. market to provide a novel solution for patients with the challenging condition of chronic high dislocation … [Read more…]
Orion to receive an upfront payment of USD 290 million Agreement strengthens and complements Merck’s oncology pipeline RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Orion Corporation (“Orion”) today announced a global development and commercialization agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 … [Read more…]
Phase 3 trial demonstrated a reduction in SARS-CoV-2 viral load in high-risk COVID-19 patients by 94% and 99% within 24 and 48 hours of treatment, respectively Median time to a negative PCR test was three days after beginning treatment in the nitric oxide group vs. seven days in the placebo group (P < 0.05) Participants … [Read more…]
Expands bioanalytical services to include many emerging areas worldwide MALVERN, Pa.–(BUSINESS WIRE)–Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital … [Read more…]
BURLINGTON, Ontario–(BUSINESS WIRE)–$ELMT—Element Nutritional Sciences Inc. (CSE:ELMT; OTC:ELNSF; FRANKFURT:93X) (the “Company” or “Element”), is pleased to announce that its latest innovation, Rejuvenate™ Immune Health, is now available to consumers on the Amazon platform in the United States through the Company’s distribution partnership with e-commerce accelerator Pattern Inc. (“Pattern”). Rejuvenate™ Immune Health is a powdered drink … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Drug Class and Distribution Channel” report has been added to ResearchAndMarkets.com’s offering. The chemotherapy-induced peripheral neuropathy market is expected to grow from US$ 813.48 million in 2021 to US$ 1,174.26 million by 2028; it is estimated to grow … [Read more…]
— Extension led by Pfizer with participation from new investors Walleye Capital and Asabys Partners as well as existing investors — — Funding will support next stage of clinical and corporate development — GHENT, Belgium–(BUSINESS WIRE)–Agomab Therapeutics NV (‘Agomab’) today announced it has extended its Series B financing round with an additional close of $40.5 … [Read more…]
